KalVista Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) (“KalVista”) announced today that it intends to offer and sell shares of its common stock and pre-funded warrants to purchase shares of common stock in lieu of KalVista common stock to certain investors in an underwritten public offering.
- KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) (“KalVista”) announced today that it intends to offer and sell shares of its common stock and pre-funded warrants to purchase shares of common stock in lieu of KalVista common stock to certain investors in an underwritten public offering.
- In addition, KalVista intends to grant the underwriters a 30-day option to purchase an additional 15% of the securities offered in the public offering at the public offering price less underwriting discounts and commissions.
- All of the shares and pre-funded warrants will be offered and sold by KalVista.
- Jefferies, Leerink Partners, Stifel and Cantor are acting as the joint book-running managers for the proposed offering.